BEIJING (Reuters) – An inhalation version of CanSino Biologics’ COVID-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said late on Wednesday.
Yu made the comment at a panel of the Global Health Forum of the Boao Forum for Asia.
(Reporting by Roxanne Liu and Ryan Woo; Editing by David Goodman)
